Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
04/06/2026 21:13
BRIEF-Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease June 4 (Reuters) - Fulcrum Therapeutics Inc FULC.O:
FULCRUM THERAPEUTICS - APPROVES RESTRUCTURING PLAN AFTER DISCONTINUING POCIREDIR FOR SICKLE CELL DISEASE - SEC FILING
FULCRUM THERAPEUTICS - TO REDUCE WORKFORCE BY 85% FROM 57 TO 9 EMPLOYEES, COMPLETION EXPECTED Q2 2026 - SEC FILING
FULCRUM THERAPEUTICS - EXPECTS AGGREGATE RESTRUCTURING CHARGES OF ABOUT $4.2 MILLION - SEC FILING
FULCRUM THERAPEUTICS - WORKFORCE REDUCTION COMMUNICATED JUNE 4, 2026; CHARGES TO BE INCURRED IN Q2 2026 - SEC FILING
Further company coverage: FULC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program